In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Conjugate Pemvidutide | Synthetic analog Semaglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Conjugate | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 43 | 4,624 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 7 (7 in people) | 1,224 (1,221 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 8 · 2 active | 663 · 284 active124 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 27 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Pemvidutide | Semaglutide |
|---|---|---|
| Body weightMetabolic and weight | 422 | 969954105 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Ozempic says: “Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes; reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; reduce the risk of sustained eGFR decline…”
| Adverse eventsWhole body | 77 | 7757723 |
|---|
| Liver fat and liver functionLiver | 281711 | 17917441 |
|---|
| LipidsMetabolic and weight | 22 | 1181171 |
|---|
| Inflammation markersLiver | 22 | 51492 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Semaglutide differs from Glucagon-like peptide 1 (7-37) at 2 positions and carries 1 added group.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Pemvidutide | Semaglutide |
|---|---|---|
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in % | −6.2% Body weight reduction · Shown as a change. The study reports a body weight reduction of this size. · pemvidutide, week 24 24 weeksn not reported2025 | −14.9% Mean weight change Placebo: −2.4% Dose studied: 2.4 mg once weekly68 weeksn = 1,9612021 |
| Liver fat and liver functionLiverCompared as: value in the arm that got the peptide, in % | 52% MASH resolution without fibrosis worsening · pemvidutide 1.8 mg, week 24 Placebo, week 24: 20% Dose studied: 1·8 mg24 weeksn = 1712025 | |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 1% Discontinuations due to adverse events · pemvidutide 1·8 mg (1 of 85) Placebo (2 of 86): 2% Dose studied: 1·8 mg24 weeksn = 1712025 |
−6.2%
Body weight reduction · Shown as a change. The study reports a body weight reduction of this size. · pemvidutide, week 24
24 weeksn not reported2025
−14.9%
Mean weight change
Placebo: −2.4%
Dose studied: 2.4 mg once weekly68 weeksn = 1,9612021
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Pemvidutide | Semaglutide |
|---|---|---|
| Inflammation markersImmune and inflammationCompared as: difference from placebo, in % | No randomized trial result 2 results from other study designs. | −18.08% hsCRP change at 13 weeks Dose studied: maximum 14 mg once dailyn = 9,6502026 |
62.9% Resolution of steatohepatitis Placebo: 34.3% Dose studied: 2.4 mg once weekly72 weeks (interim analysis; planned 240 weeks)n = 8002025 |
16.6%
discontinuation due to adverse events
Placebo: 8.2%
Dose studied: 2.4 mg once weeklyn = 17,6042023
52%
MASH resolution without fibrosis worsening · pemvidutide 1.8 mg, week 24
Placebo, week 24: 20%
Dose studied: 1·8 mg24 weeksn = 1712025
62.9%
Resolution of steatohepatitis
Placebo: 34.3%
Dose studied: 2.4 mg once weekly72 weeks (interim analysis; planned 240 weeks)n = 8002025
1%
Discontinuations due to adverse events · pemvidutide 1·8 mg (1 of 85)
Placebo (2 of 86): 2%
Dose studied: 1·8 mg24 weeksn = 1712025
16.6%
discontinuation due to adverse events
Placebo: 8.2%
Dose studied: 2.4 mg once weeklyn = 17,6042023
| LipidsMetabolic and weightCompared as: difference from placebo, in % | No randomized trial result 2 results from other study designs. | −7% Total cholesterol change at 13 weeks Dose studied: maximum 14 mg once dailyn = 9,6502026 |
|---|
No randomized trial result
2 results from other study designs.
−18.08%
hsCRP change at 13 weeks
Dose studied: maximum 14 mg once dailyn = 9,6502026
No randomized trial result
2 results from other study designs.
−7%
Total cholesterol change at 13 weeks
Dose studied: maximum 14 mg once dailyn = 9,6502026
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 8 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)
Altimmune, Inc.1,800 participants30 Jul 2026 to est. Dec 2032
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Altimmune, Inc.212 participants27 Jul 2023 to 25 Nov 2025
Non-Alcoholic Steatohepatitis (NASH)
Altimmune, Inc.121 participants16 Jun 2025 to est. 30 Sept 2027
Alcohol-associated Liver Disease
Top 3 of 663 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S17,604 participants24 Oct 2018 to 29 Jun 2023
Overweight · Obesity
Novo Nordisk A/S9,651 participants17 Jun 2019 to 23 Aug 2024
Diabetes Mellitus, Type 2
Novo Nordisk A/S3,533 participants17 Jun 2019 to 9 Jan 2024
Diabetes Mellitus, Type 2
124 more mention it but do not test it. They only measure it or name it in their text.